EU citizens hoping to speak about valproate-containing medicines at the European Medicines Agency’s first ever public hearing on the safety of marketed medicines in September are being asked to consider three questions relating to their experience with such drugs during pregnancy.
The EMA will choose speakers for the hearing based on how they propose to address the questions, which the agency published today, together with practical information on
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?